Published in J Invest Dermatol on June 14, 2012
IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Invest Dermatol (2013) 1.65
Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients. J Invest Dermatol (2015) 1.52
CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med (2014) 1.50
A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Exp Dermatol (2013) 1.50
Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J Invest Dermatol (2014) 1.03
Activation of the unfolded protein response in vitiligo: the missing link? J Invest Dermatol (2012) 1.03
Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol (2013) 0.97
Vitiligo--part 1. An Bras Dermatol (2014) 0.96
Understanding mechanisms of autoimmunity through translational research in vitiligo. Curr Opin Immunol (2016) 0.86
The role of transcription factor Nrf2 in skin cells metabolism. Arch Dermatol Res (2015) 0.83
Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev (2016) 0.80
Vitiligo and alopecia areata: apples and oranges? Exp Dermatol (2013) 0.79
A Multicenter Collaborative Study by the Korean Society of Vitiligo about Patients' Occupations and the Provoking Factors of Vitiligo. Ann Dermatol (2014) 0.79
Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin: relevance to early vitiligo. Clin Exp Dermatol (2013) 0.78
Interferon-γ induces senescence in normal human melanocytes. PLoS One (2014) 0.77
Recent Insights into the Role of Unfolded Protein Response in ER Stress in Health and Disease. Front Cell Dev Biol (2017) 0.77
Loss of Oca2 disrupts the unfolded protein response and increases resistance to endoplasmic reticulum stress in melanocytes. Pigment Cell Melanoma Res (2013) 0.76
Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr (2016) 0.76
Whole Transcriptome Analysis (RNA Sequencing) of Peripheral Blood Mononuclear Cells of Vitiligo Patients. Dermatopathology (Basel) (2014) 0.75
Differential responses of normal human melanocytes to intra- and extracellular dsRNA. DNA Cell Biol (2015) 0.75
Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo. Exp Dermatol (2014) 0.75
Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin (2017) 0.75
IRE1α-XBP1 pathway promotes melanoma progression by regulating IL-6/STAT3 signaling. J Transl Med (2017) 0.75
Recent advances in understanding vitiligo. F1000Res (2016) 0.75
Heat Shock Protein-70 Expression in Vitiligo and its Relation to the Disease Activity. Indian J Dermatol (2016) 0.75
The nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant response promotes melanocyte viability and reduces toxicity of the vitiligo-inducing phenol monobenzone. Exp Dermatol (2017) 0.75
Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol (2007) 33.06
The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem (2009) 5.80
The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol (2008) 4.09
Interleukin-6 and chronic inflammation. Arthritis Res Ther (2006) 3.74
Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science (2011) 3.29
IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev (2002) 2.99
The unfolded protein response is an important regulator of inflammatory genes in endothelial cells. Arterioscler Thromb Vasc Biol (2006) 2.90
PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J Biol Chem (2004) 2.74
Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int J Biochem Cell Biol (2005) 2.12
Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71
Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab (1996) 1.68
Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease. J Biol Chem (2011) 1.58
Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56
On the etiology of contact/occupational vitiligo. Pigment Cell Res (2004) 1.55
Antibodies to normal human melanocytes in vitiligo. J Exp Med (1983) 1.50
Endoplasmic reticulum stress in beta-cells and development of diabetes. Curr Opin Pharmacol (2009) 1.41
Vitiligo puzzle: the pieces fall in place. Pigment Cell Res (2007) 1.39
Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol (1996) 1.35
Autoimmune aspects of vitiligo. Autoimmunity (2001) 1.30
The UPR and cell fate at a glance. J Cell Sci (2010) 1.30
An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol (1993) 1.21
4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol (2005) 1.20
The role of oxidants and antioxidants in generalized vitiligo. J Dermatol (2003) 1.19
Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res (1995) 1.18
Occupational vitiligo induced by p-tert-butylphenol, a systemic disease? Lancet (1977) 1.17
The role of oxidants and antioxidants in generalized vitiligo at tissue level. J Eur Acad Dermatol Venereol (2004) 1.11
Heme oxygenase-1 protects human melanocytes from H2O2-induced oxidative stress via the Nrf2-ARE pathway. J Invest Dermatol (2011) 1.09
Genetic variation of promoter sequence modulates XBP1 expression and genetic risk for vitiligo. PLoS Genet (2009) 1.07
The genetics of generalized vitiligo: autoimmune pathways and an inverse relationship with malignant melanoma. Genome Med (2010) 1.07
Endoplasmic reticulum stress-induced apoptosis and auto-immunity in diabetes. Curr Mol Med (2006) 1.05
Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J Invest Dermatol (1991) 1.04
Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol (1997) 1.04
Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: evidence for a regulatory role of IL-6, IL-7, TNF beta, and UVB light. J Invest Dermatol (1992) 1.02
Heme oxygenase-1 inhibits T cell-dependent skin inflammation and differentiation and function of antigen-presenting cells. Exp Dermatol (2007) 1.02
Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation. J Clin Immunol (2008) 1.02
Subtoxic levels hydrogen peroxide-induced production of interleukin-6 by retinal pigment epithelial cells. Mol Vis (2010) 1.02
Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. Int J Dermatol (2006) 1.00
Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. Histol Histopathol (2009) 0.98
Rapamycin inhibits postprandial-mediated X-box-binding protein-1 splicing in rat liver. J Nutr (2010) 0.98
Vitiligo. Semin Cutan Med Surg (1997) 0.98
A role for tyrosinase-related protein 1 in 4-tert-butylphenol-induced toxicity in melanocytes: Implications for vitiligo. Am J Pathol (2006) 0.95
Dominance of activated T cells and interleukin-6 in aqueous humor in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci (1994) 0.94
PIG3V, an immortalized human vitiligo melanocyte cell line, expresses dilated endoplasmic reticulum. In Vitro Cell Dev Biol Anim (2000) 0.93
Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation. J Invest Dermatol (2010) 0.93
Increased interleukin-6 and granulocyte-macrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo. J Dermatol Sci (2003) 0.90
Dermatitis produced by applications of monobenzone in patients with active vitiligo. Arch Dermatol (1985) 0.86
Characterization of T-cell subsets, soluble interleukin-2 receptors and interleukin-6 in Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol (1992) 0.85
Heme oxygenase-1 expression protects melanocytes from stress-induced cell death: implications for vitiligo. Exp Dermatol (2011) 0.85
Biologic characteristics of cultured human vitiligo melanocytes. Int J Dermatol (1994) 0.84
Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition. Int J Oncol (2010) 0.82
IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-DR and intercellular adhesion molecule-1 expression and an increase in interleukin-8 release by melanocytes. J Invest Dermatol (2000) 0.81
[Interleukin-11, an IL-6 like cytokine]. Mol Biol (Mosk) (2011) 0.79
p16(Ink4a) in melanocyte senescence and differentiation. J Natl Cancer Inst (2002) 2.09
IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Invest Dermatol (2013) 1.65
Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol (2006) 1.55
On the etiology of contact/occupational vitiligo. Pigment Cell Res (2004) 1.55
Symmetric truncal aplasia cutis congenita following multifetal reduction of a sextuplet pregnancy. J Pediatr (2008) 1.48
Dissection of melanogenesis with small molecules identifies prohibitin as a regulator. Chem Biol (2005) 1.48
Spitz nevi: beliefs, behaviors, and experiences of pediatric dermatologists. JAMA Dermatol (2013) 1.46
Triazine-based tyrosinase inhibitors identified by chemical genetic screening. Pigment Cell Res (2005) 1.40
Pink-eyed dilution protein controls the processing of tyrosinase. Mol Biol Cell (2002) 1.29
Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation. FASEB J (2010) 1.23
Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res (2008) 1.21
Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transl Res (2009) 1.17
Pink-eyed dilution protein modulates arsenic sensitivity and intracellular glutathione metabolism. Mol Biol Cell (2002) 1.14
The misnomer "macrocephaly-cutis marmorata telangiectatica congenita syndrome": report of 12 new cases and support for revising the name to macrocephaly-capillary malformations. Arch Dermatol (2009) 1.10
Identification of novel pigmentation modulators by chemical genetic screening. J Invest Dermatol (2007) 1.06
Pityriasis rubra pilaris, type IV. Dermatol Online J (2005) 1.03
Practical guidelines for evaluation of loose anagen hair syndrome. Arch Dermatol (2009) 1.02
Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. Clin Cancer Res (2009) 1.01
Mutations in the desmoglein 4 gene underlie localized autosomal recessive hypotrichosis with monilethrix hairs and congenital scalp erosions. J Invest Dermatol (2006) 1.00
The Tyr (albino) locus of the laboratory mouse. Mamm Genome (2004) 1.00
Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics (2013) 1.00
Porokeratotic eccrine ostial and dermal duct nevus: a report of 2 cases and review of the literature. Am J Dermatopathol (2009) 0.99
Degradation of tyrosinase induced by phenylthiourea occurs following Golgi maturation. Pigment Cell Res (2005) 0.99
Infantile systemic hyalinosis. J Am Acad Dermatol (2004) 0.99
From the rarest to the most common: insights from progeroid syndromes into skin cancer and aging. J Invest Dermatol (2009) 0.99
"Pediatric blaschkitis": expanding the spectrum of childhood acquired Blaschko-linear dermatoses. Pediatr Dermatol (2007) 0.96
Ocular albinism 1 protein: trafficking and function when expressed in Saccharomyces cerevisiae. Exp Eye Res (2005) 0.96
Ehlers-Danlos syndrome type VIII: periodontitis, easy bruising, marfanoid habitus, and distinctive facies. J Am Acad Dermatol (2006) 0.95
Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma. Melanoma Res (2010) 0.94
Planning for a brighter future: a review of sun protection and barriers to behavioral change in children and adolescents. Dermatol Online J (2008) 0.94
Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Mol Cancer Res (2009) 0.94
Identification of quinolines that inhibit melanogenesis by altering tyrosinase family trafficking. Mol Pharmacol (2008) 0.93
Oxidative stress activates FUS1 and RLM1 transcription in the yeast Saccharomyces cerevisiae in an oxidant-dependent Manner. Mol Biol Cell (2004) 0.92
The Dermatology Foundation: partnerships and programs focused on the future. J Invest Dermatol (2013) 0.92
Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism. Cancer Chemother Pharmacol (2008) 0.91
Extensive Riga-Fede disease of the lip and tongue. J Am Acad Dermatol (2002) 0.91
Mucosal dominant pemphigus vulgaris with anti-desmoplakin autoantibodies. J Am Acad Dermatol (2004) 0.90
Experience with molluscum contagiosum and associated inflammatory reactions in a pediatric dermatology practice: the bump that rashes. Arch Dermatol (2012) 0.90
The ocular albinism type 1 gene product, OA1, spans intracellular membranes 7 times. Exp Eye Res (2007) 0.89
Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells. Mol Cancer Res (2009) 0.88
Rab27b association with melanosomes: dominant negative mutants disrupt melanosomal movement. J Invest Dermatol (2002) 0.88
Fluvastatin enhances sorafenib cytotoxicity in melanoma cells via modulation of AKT and JNK signaling pathways. Anticancer Res (2011) 0.88
Mucocutaneous neuromas: an underrecognized manifestation of PTEN hamartoma-tumor syndrome. Arch Dermatol (2006) 0.87
XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. Anticancer Drugs (2013) 0.86
Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol (2003) 0.86
Heterologous expression of tyrosinase recapitulates the misprocessing and mistrafficking in oculocutaneous albinism type 2: effects of altering intracellular pH and pink-eyed dilution gene expression. Exp Eye Res (2005) 0.85
Accumulation of tyrosinase in the endolysosomal compartment is induced by U18666A. Pigment Cell Res (2003) 0.85
Pigmented plexiform neurofibroma: Distinction from a large congenital melanocytic nevus. J Am Acad Dermatol (2007) 0.84
The unfolded protein response in melanocytes: activation in response to chemical stressors of the endoplasmic reticulum and tyrosinase misfolding. Pigment Cell Melanoma Res (2010) 0.84
Abortive segmental perineal hemangioma. Dermatol Online J (2011) 0.84
Identification of the F1F0 mitochondrial ATPase as a target for modulating skin pigmentation by screening a tagged triazine library in zebrafish. Mol Biosyst (2005) 0.84
Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways. Oncol Rep (2012) 0.83
Radiation therapy for high-risk squamous cell carcinomas in patients with xeroderma pigmentosum: report of two cases and review of the literature. Dermatology (2011) 0.82
Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literature. J Am Acad Dermatol (2005) 0.82
Correction of defective early tyrosinase processing by bafilomycin A1 and monensin in pink-eyed dilution melanocytes. Pigment Cell Res (2004) 0.81
Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism. Leuk Res (2009) 0.81
Cole Disease Results from Mutations in ENPP1. Am J Hum Genet (2013) 0.80
25-hydroxycholesterol acts in the Golgi compartment to induce degradation of tyrosinase. Pigment Cell Res (2004) 0.80
Albendazole sensitizes cancer cells to ionizing radiation. Radiat Oncol (2011) 0.79
Report of a novel OCA2 gene mutation and an investigation of OCA2 variants on melanoma risk in a familial melanoma pedigree. J Dermatol Sci (2012) 0.79
Identification of compounds that bind mitochondrial F1F0 ATPase by screening a triazine library for correction of albinism. Chem Biol (2004) 0.78
Cole disease: guttate hypopigmentation and punctate palmoplantar keratoderma. Arch Dermatol (2009) 0.77
Efficacy and safety of oral retinoids in psoriasis. Expert Opin Drug Saf (2005) 0.77
DeoxyArbutin and its derivatives inhibit tyrosinase activity and melanin synthesis without inducing reactive oxygen species or apoptosis. J Drugs Dermatol (2012) 0.77
Lichen planopilaris noted during etanercept therapy in a child with severe psoriasis. Pediatr Dermatol (2009) 0.77
Chemical genetic screening identifies tricyclic compounds that decrease cellular melanin content. J Invest Dermatol (2007) 0.77
Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol (2010) 0.76
Loss of Oca2 disrupts the unfolded protein response and increases resistance to endoplasmic reticulum stress in melanocytes. Pigment Cell Melanoma Res (2013) 0.76
X-linked recessive ichthyosis. Dermatol Online J (2005) 0.76
Congenital Spitz nevus clinically mimicking melanoma. J Am Acad Dermatol (2002) 0.76
The physician-scientist. J Invest Dermatol (2006) 0.76
Juvenile myelomonocytic leukemia presenting with features of hemophagocytic lymphohistiocytosis in association with neurofibromatosis and juvenile xanthogranulomas. J Pediatr Hematol Oncol (2004) 0.76
Informed reasoning: repositioning of nitisinone to treat oculocutaneous albinism. J Clin Invest (2011) 0.75
Identification of agents that promote endoplasmic reticulum stress using an assay that monitors luciferase secretion. J Biomol Screen (2013) 0.75
Melanocytic proliferations in the setting of vulvar lichen sclerosus: diagnostic considerations. Pediatr Dermatol (2005) 0.75
Engineering a new mouse model for vitiligo. J Invest Dermatol (2012) 0.75
Juvenile amyopathic dermatomyositis. Dermatol Online J (2005) 0.75
Morphea, diabetes mellitus type I, and celiac disease: case report and review of the literature. Pediatr Dermatol (2010) 0.75
Dermatologists' attitudes, prescription, and counseling patterns for isotretinoin: a questionnaire-based study. J Drugs Dermatol (2015) 0.75
Eccrine angiomatous hamartoma. Dermatol Online J (2006) 0.75
Infantile granular parakeratosis: recognition of two clinical patterns. J Am Acad Dermatol (2004) 0.75
Cutaneous features of Crouzon syndrome with acanthosis nigricans. JAMA Dermatol (2013) 0.75
Phacomatosis pigmentokeratotica associated with hemihypertrophy and a rhabdomyosarcoma of the abdominal wall. J Am Acad Dermatol (2006) 0.75